A Phase 1, Open-Label, Single Dose Study to Evaluate the Pharmacokinetics of Ampreloxetine Following a Single-dose in Subjects With Mild, Moderate, and Severe Hepatic Impairment and in Matching Healthy Subjects
Latest Information Update: 26 Dec 2022
At a glance
- Drugs Ampreloxetine (Primary)
- Indications Orthostatic hypotension
- Focus Pharmacokinetics
- Sponsors Theravance Biopharma
Most Recent Events
- 08 Nov 2022 Results presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases.
- 27 Sep 2022 Primary endpoint (Plasma Cmax) has been met, according to Results presented at the 2022 American College of Clinical Pharmacology Annual Meeting.
- 27 Sep 2022 Primary endpoint (Plasma AUC0-inf) has been met, according to Results presented at the 2022 American College of Clinical Pharmacology Annual Meeting.